Copyright
©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
To explore the mechanism of Yigong San anti-gastric cancer and immune regulation
Dou-Dou Lu, Ling Yuan, Zhao-Zhao Wang, Jian-Jun Zhao, Yu-Hua Du, Na Ning, Guo-Qing Chen, Shi-Cong Huang, Yi Yang, Zhe Zhang, Yi Nan
Dou-Dou Lu, School of Clinical Medicine, Ningxia Medical University, Yinchuan 750004, Ningxia Hui Autonomous Region, China
Ling Yuan, Jian-Jun Zhao, Yu-Hua Du, Na Ning, Guo-Qing Chen, Shi-Cong Huang, Yi Yang, College of Pharmacy, Ningxia Medical University, Yinchuan 750004, Ningxia Hui Autonomous Region, China
Zhao-Zhao Wang, Traditional Chinese Medicine College, Ningxia Medical University, Yinchuan 750004, Ningxia Hui Autonomous Region, China
Zhe Zhang, Department of Chinese Medical Gastrointestinal, China-Japan Friendship Hospital, Beijing 100029, China
Yi Nan, Key Laboratory of Ningxia Minority Medicine Modernization Ministry of Education, Ningxia Medical University, Yinchuan 750004, Ningxia Hui Autonomous Region, China
Author contributions: Lu DD performed the research and wrote the paper; Yuan L, Zhang Z and Nan Y designed the research; Zhao JJ, Du YH and Ning N contributed new analytic tools; Wang ZZ, Chen GQ, Huang SC and Yang Y analyzed the data.
Supported by Ningxia Key Research and Development Program, No. 2023BEG02015; Ningxia Science and Technology Benefiting People Program, No. 2022CMG03064; Ningxia Natural Science Foundation, No. 2022AAC02039; and National Natural Science Foundation of China, No. 82260879 and No. 82374261.
Institutional review board statement: No animal experiments or human clinical trials are involved in this manuscript.
Informed consent statement: No clinical trials are involved in this manuscript.
Conflict-of-interest statement: All authors declare no financial or commercial conflict of interest for this manuscript.
Data sharing statement: All data generated or analyzed during this study are included in this paper, and further inquiries can be directed to the corresponding author (E-mail: 20080011@nxmu.edu.cn).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:
https://creativecommons.org/Licenses/by-nc/4.0/ Corresponding author: Yi Nan, PhD, Professor, Key Laboratory of Ningxia Minority Medicine Modernization Ministry of Education, Ningxia Medical University, No. 1160 Shengli Street, Yinchuan 750004, Ningxia Hui Autonomous Region, China. 20080011@nxmu.edu.cn
Received: December 20, 2023
Peer-review started: December 20, 2023
First decision: January 10, 2024
Revised: January 21, 2024
Accepted: February 20, 2024
Article in press: February 20, 2024
Published online: May 15, 2024
Processing time: 141 Days and 1.5 Hours
BACKGROUND
Yigong San (YGS) is a representative prescription for the treatment of digestive disorders, which has been used in clinic for more than 1000 years. However, the mechanism of its anti-gastric cancer and regulate immunity are still remains unclear.
AIM
To explore the mechanism of YGS anti-gastric cancer and immune regulation.
METHODS
Firstly, collect the active ingredients and targets of YGS, and the differentially expressed genes of gastric cancer. Secondly, constructed a protein-protein interaction network between the targets of drugs and diseases, and screened hub genes. Then the clinical relevance, mutation and repair, tumor microenvironment and drug sensitivity of the hub gene were analyzed. Finally, molecular docking was used to verify the binding ability of YGS active ingredient and hub genes.
RESULTS
Firstly, obtained 55 common targets of gastric cancer and YGS. The Kyoto Encyclopedia of Genes and Genomes screened the microtubule-associated protein kinase signaling axis as the key pathway and IL6, EGFR, MMP2, MMP9 and TGFB1 as the hub genes. The 5 hub genes were involved in gastric carcinogenesis, staging, typing and prognosis, and their mutations promote gastric cancer progression. Finally, molecular docking results confirmed that the components of YGS can effectively bind to therapeutic targets.
CONCLUSION
YGS has the effect of anti-gastric cancer and immune regulation.
Core Tip: Gastric cancer seriously endangers human life and quality of life. Traditional Chinese medicine has rich experience in treating tumors, and Yigong San (YGS) is a representative prescription that can treat a variety of digestive system diseases, but there is no study on the anti-gastric cancer effect of YGS. In this study, we used network pharmacology and bioinformatics methods to analyze the anti-gastric cancer mechanism of YGS, and to provide basis for the clinical treatment of gastric cancer.
